MEN1703

Phase 2Small molecule

Menarini

MEN1703 is one of 59 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Norvir

AbbVie

Preclinical

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

MEN1703

Menarini

Phase 2

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Lymphoma

NCT06534437

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

Completed· Menarini logo

Menarini·Phase 1/2·NCT03008187·73 enrolled

Lymphoma1 trial

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Recruiting·RRyvu Therapeutics SA·Phase 2·NCT06534437·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MEN1703. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEN1703 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEN1703. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menarini company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Menarini

MEN1703

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News